Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Epogen boosts hematocrit levels in anemic ESRD patients, improves quality of life, study says.

Executive Summary

AMGEN EPOGEN RAISES HEMATOCRIT LEVELS UP TO 30% FROM 26% AT BASELINE at first follow-up reported in kidney dialysis patients who were treated with epoietin alfa therapy for anemia. The patients were part of the 2,100-person open-label, multi-center National Cooperative Recombinant Human Erythropoietin Study published in the May issue of the Journal of the American Society of Nephrology. At the time of the Amgen-sponsored study, which began in 1990, recommended hematocrit ranges were 30%-33%; the recommended range since has been broadened to 30%-36%, Amgen noted.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028242

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel